Improved treatment of multidrug-resistant bacterial infections: Utility of clinical studies

Future Microbiology

Volumn 9, Issue 6, 2014, Pages 757-771

  Bettiol, Esther ^a   Rottier, Wouter C ^b   Del Toro, Maria Dolores ^c,d   Harbarth, Stephan ^a   Bonten, Marc J ^b   Rodríguez Baño, Jesús ^c,d  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Unidad de Enfermedades Infecciosas y Microbiología   (Spain)

^d UNIVERSITY OF SEVILLE   (Spain)

Author keywords

antibacterial resistance; antibacterial treatment; clinical trials; epidemiology; interventional; multidrug resistant organisms; observational; pharmacokinetic pharmacodynamic; regulatory guidance; study design

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFMETAZOLE; CEFPIROME; CEPHAMYCIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; FLOMOXEF; FOSFOMYCIN; IMIPENEM; MEROPENEM; PIPERACILLIN; QUINOLONE DERIVATIVE; TEMOCILLIN; TIGECYCLINE; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; DRUG EFFICACY; DRUG SAFETY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HEALTH CARE COST; HUMAN; INTERVENTION STUDY; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; BACTERIAL INFECTIONS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 84904596917     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.35     Document Type: Review

References (110)

1. Carlet J, Collignon P, Goldmann D et al. Society's failure to protect a precious resource: Antibiotics. Lancet 378(9788), 369-371 (2011
2. ECDC/EMEA Joint Technical Report, the bacterial challenge: Time to react (2009). www.ecdc.europa.eu/en/publications/ Publications/0909-TER-The-Bacterial- Challenge-Time-to-React.pdf
3. CDC Report. Antibiotic resistance threats in the United States (2013). www.cdc.gov/drugresistance/threatreport-2013
4. Molton JS, Tambyah PA, Ang BS, Ling ML, Fisher DA. The global spread of healthcareassociated multidrug-resistant bacteria: A perspective from Asia. Clin. Infect. Dis. 56(9), 1310-1318 (2013
5. Spellberg B, Guidos R, Gilbert D et al. The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46(2), 155-164 (2008
6. Jarlier V, Carlet J, Mcgowan J et al. Priority actions to fight antibiotic resistance: Results of an international meeting. Antimicrob. Resist. Infect. Control. 1(1), 17 (2012
7. Lynch TJ. Choosing optimal antimicrobial therapies. Med. Clin. North Am. 96(6), 1079-1094 (2012
8. Gazin M, Paasch F, Goossens H, Malhotra-Kumar S. Current trends in culture-based and molecular detection of extended-spectrumbeta-lactamase- harboring and carbapenemresistant Enterobacteriaceae. J. Clin. Microbiol. 50(4), 1140-1146 (2012
9. Livermore DM. Fourteen years in resistance. Int. J. Antimicrob. Agents 39(4), 283-294 (2012
10. Dautzenberg MJD, Ossewaarde JM, De Kraker MEA et al. Successful control of hospital-wide outbreak of OXA-48 producing Enterobacteriaceae in The Netherlands. Euro. Surveill. 19, 20723 (2014
11. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18(3), 268-281 (2012
12. Ammerlaan HS, Harbarth S, Buiting AG et al. Secular trends in nosocomial bloodstream infections: Antibiotic-resistant bacteria increase the total burden of infection. Clin. Infect. Dis. 56(6), 798-805 (2013
13. Rodriguez-Baño J, Mingorance J, Fernandez-Romero N, Serrano L, Lopez-Cerero L, Pascual A. Outcome of bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli: Impact of microbiological determinants. J. Infect. 67(1), 27-34 (2013).
14. Stewardson A, Fankhauser C, De Angelis G et al. Burden of bloodstream infection caused by extended-spectrum beta-lactamaseproducing Enterobacteriaceae determined using multistate modeling at a Swiss University Hospital and a nationwide predictive model. Infect. Control Hosp. Epidemiol. 34(2), 133-143 (2013
15. Boucher HW, Talbot GH, Benjamin DK Jr et al. 10 20 progress -development of new drugs active against Gram-negative bacilli: An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 56(12), 1685-1694 (2013
16. Khan AR, Khan S, Zimmerman V, Baddour LM, Tleyjeh IM. Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines. Clin. Infect. Dis. 51(10), 1147-1156 (2010
17. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95 rev 2). Committee for Medicinal Products for Human Use, EMA. www.ema.europa.eu/docs/en-GB/ document-library/ Scientific- guideline/2009/09/WC500003417.pdf
18. ESCMID operating procedures for medical guidelines. www.escmid.org/ membership-organization/ about-escmid/operating-procedures/ eops-for-medical- guidelines
19. IDSA Practise Guidelines. www.idsociety.org/IDSA-Practice- Guidelines
20. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemaseproducing Gram-negative bacteria. Clin. Microbiol. Infect. 18(5), 439-448 (2012
21. Chu H, Zhao L, Wang M, Liu Y, Gui T, Zhang J. Sulbactam-based therapy for Acinetobacter baumannii infection: A systematic review and meta-Analysis. Braz. J. Infect. Dis. 17(4), 389-394 (2013
22. Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: A meta-Analysis. Lancet Infect. Dis. 11(11), 834-844 (2012
23. Curcio D. Off-label use of antibiotics in intensive care unit: The multidrug-resistant pathogens challenge. J. Crit. Care 26(1), 95-96 (2011
24. Lat I, Micek S, Janzen J, Cohen H, Olsen K, Haas C. Off-label medication use in adult critical care patients. J. Crit. Care 26(1), 89-94 (2011
25. Livni G, Ashkenazi S. Treatment of resistant bacterial infections in children: Thinking inside and outside the box. Adv. Exp. Med. Biol. 764, 123-132 (2013
26. Tansarli GS, Rafailidis PI, Kapaskelis A, Falagas ME. Frequency of the off-label use of antibiotics in clinical practice: A systematic review. Expert Rev. Anti Infect. Ther. 10(12), 1383-1392 (2012
27. Ammerlaan H, Seifert H, Harbarth S et al. Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 western European countries. Clin. Infect. Dis. 49(7), 997-1005 (2009
28. Harbarth S, Rutschmann O, Sudre P, Pittet D. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch. Intern. Med. 158(2), 182-189 (1998
29. IDSA White paper: Recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drugresistant bacterial pathogens. Clin. Infect. Dis. 55(8), 1031-1046 (2012
30. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: Epidemiology, diagnosis and management in immunocompromised patients. Drugs 67(11), 1567-1601 (2007
31. Kalil AC, Klompas M, Haynatzki G, Rupp ME. Treatment of hospital-Acquired pneumonia with linezolid or vancomycin: A systematic review and meta-Analysis. BMJ Open 3(10), e003912 (2013
32. Logman JF, Stephens J, Heeg B et al. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Curr. Med. Res. Opin. 26(7), 1565-1578 (2010
33. Vardakas KZ, Mavros MN, Roussos N, Falagas ME. Meta-Analysis of randomized controlled trials of vancomycin for the treatment of patients with Gram-positive infections: Focus on the study design. Mayo Clin. Proc. 87(4), 349-363 (2012
34. Whang DW, Miller LG, Partain NM, McKinnell JA. Systematic review and meta-Analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections. Antimicrob. Agents. Chemother. 57(10), 5013-5018 (2013
35. Van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: A systematic review and meta-Analysis. Clin. Infect. Dis. 54(6), 755-771 (2012
36. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: A case-control study. Clin. Infect. Dis. 54(1), 51-58 (2012
37. Murray KP, Zhao JJ, Davis SL et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration 1 mg/l: A matched cohort study. Clin. Infect. Dis. 56(11), 1562-1569 (2013
38. Lopez-Cortes LE, Pascual A, Rodr?guez-Ba?o J. Daptomycin or vancomycin for methicillinresistant Staphylococcus aureus with a vancomycin minimum inhibitory concentration 1 ug/l. Clin. Infect. Dis. 54(9), 1375-1376; author reply 1376-1377 (2012
39. Weston A, Boucher HW. Early high-dose daptomycin for methicillin- resistant Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentrations: Ready for prime time?. Clin. Infect. Dis. 56(11), 1570-1572 (2013
40. Carrillo-Marquez MA, Hulten KG, Hammerman W, Lamberth L, Mason EO, Kaplan SL. Staphylococcus aureus pneumonia in children in the era of community-Acquired methicillin-resistance at Texas Children's Hospital. Pediatr. Infect. Dis. J. 30(7), 545-550 (2011
41. Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: A review of microbiological, animal and clinical studies. Expert Opin. Investig. Drugs 18(7), 921-944 (2009
42. Goldberg E, Paul M, Talker O et al. Co-Trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: A retrospective cohort study. J. Antimicrob. Chemother. 65(8), 1779-1783 (2010
43. Peltola H, Paakkonen M, Kallio P, Kallio MJ. Clindamycin vs. first-generation cephalosporins for acute osteoarticular infections of childhood -A prospective quasi-randomized controlled trial. Clin. Microbiol. Infect. 18(6), 582-589 (2012
44. Durante-Mangoni E, Signorielo G, Andini R et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: A multicenter, randomized clinical trial. Clin. Infect. Dis. 57(3), 349-358 (2013
45. Aydemir H, Akduman D, Piskin N et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenemresistant Acinetobacter baumannii ventilatorassociated pneumonia. Epidemiol. Infect. 141(6), 1214-1222 (2013
46. Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae and patient outcome: A meta-Analysis. J. Antimicrob. Chemother. 67(6), 1311-1320 (2012
47. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: A systematic review and meta-Analysis. J. Antimicrob. Chemother. 67(12), 2793-2803 (2012
48. Doi A, Shimada T, Harada S, Iwata K, Kamiya T. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int. J. Infect. Dis. 17(3), e159-e163 (2013
49. Lee CH, Su LH, Tang YF, Liu JW. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: A retrospective study and laboratory analysis of the isolates. J. Antimicrob. Chemother. 58(5), 1074-1077 (2006
50. Yang CC, Li SH, Chuang FR et al. Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum betalactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis. BMC Infect Dis. 12, 206 (2012
51. Chopra T, Marchaim D, Veltman J et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-beta-lactamaseproducing Klebsiella pneumoniae and Escherichia coli. Antimicrob. Agents Chemother. 56(7), 3936-3942 (2012
52. Goethaert K, Van Looveren M, Lammens C et al. High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. Clin. Microbiol. Infect. 12(1), 56-62 (2006
53. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin. Infect. Dis. 56(4), 488-495 (2013
54. Rodriguez-Baño J, Picon E, Navarro MD, Lopez-Cerero L, Pascual A. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum beta-lactamaseproducing Escherichia coli. Clin. Microbiol. Infect. 18(9), 894-900 (2012
55. Rodriguez-Baño J, Navarro MD, Retamar P, Picon E, Pascual A. Beta-lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: A post hoc analysis of prospective cohorts. Clin. Infect. Dis. 54(2), 167-174 (2012
56. Spencer RC. Temocillin. J. Antimicrob. Chemother. 26(6), 735-737 (1990
57. Carmeli Y, Akova M, Cornaglia G et al. Controlling the spread of carbapenemaseproducing Gram-negatives: Therapeutic approach and infection control. Clin. Microbiol. Infect. 16(2), 102-111 (2010
58. Qureshi ZA, Paterson DL, Potoski BA et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: Superiority of combination antimicrobial regimens. Antimicrob. Agents Chemother. 56(4), 2108-2113 (2012
59. Tumbarello M, Viale P, Viscoli C et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: Importance of combination therapy. Clin. Infect. Dis. 55(7), 943-950 (2012
60. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?. Clin. Microbiol. Infect. 17(8), 1135-1141 (2011
61. Rosenbaum PR. Observational studies (2nd Edition). Springer, NY, USA (2002
62. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 20(4), 488-495 (2009
63. Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Is prolonged antibiotic prophylaxis after major surgery associated with an increased risk of nosocomial bloodstream infection?. J. Am. Coll. Surg. 190(4), 503-504 (2000
64. Bagley SC, White H, Golomb BA. Logistic regression in the medical literature: Standards for use and reporting, with particular attention to one medical domain. J. Clin. Epidemiol. 54(10), 979-985 (2001
65. Katz MH. Multivariable analysis: A primer for readers of medical research. Ann. Intern. Med. 138(8), 644-650 (2003
66. D'Agostino RB Jr, D'Agostino RB Sr. Estimating treatment effects using observational data. JAMA 297(3), 314-316 (2007
67. Chen HC, Lin WL, Lin CC et al. Outcome of inadequate empirical antibiotic therapy in emergency department patients with community-onset bloodstream infections. J. Antimicrob. Chemother. 68(4), 947-953 (2013
68. Choudhury G, Mandal P, Singanayagam A, Akram AR, Chalmers JD, Hill AT. Seven-day antibiotic courses have similar efficacy to prolonged courses in severe communityacquired pneumonia -A propensity-Adjusted analysis. Clin. Microbiol. Infect. 17(12), 1852-1858 (2011
69. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am. J. Med. 115(7), 529-535 (2003
70. Retamar P, Portillo MM, Lopez-Prieto MD et al. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: A propensity score-based analysis. Antimicrob. Agents Chemother. 56(1), 472-478 (2012
71. Heinze G, Juni P. An overview of the objectives of and the approaches to propensity score analyses. Eur. Heart J. 32(14), 1704-1708 (2011
72. De Angelis G, Murthy A, Beyersmann J, Harbarth S. Estimating the impact of healthcare-Associated infections on length of stay and costs. Clin. Microbiol. Infect. 16(12), 1729-1735 (2010
73. McGregor JC, Rich SE, Harris AD et al. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin. Infect. Dis. 45(3), 329-337 (2007
74. Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-Analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob. Agents Chemother. 54(11), 4851-4863 (2010
75. ClinicalTrials.gov. https://clinicaltrials.gov
76. Loder E, Groves T, Macauley D. Registration of observational studies. The next step towards research transparency. BMJ 340, C950 (2010
77. Thomas L, Peterson ED. The value of statistical analysis plans in observational research: Defining high-quality research from the start. JAMA 308(8), 773-774 (2012
78. Pagani L, Afshari A, Harbarth S. Year in review 2010: Critical care -infection. Crit. Care 15(6), 238 (2011
79. Goncalves-Pereira J, Povoa P. Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of beta-lactams. Crit. Care 15(5), R206 (2011
80. Mouton JW, Ambrose PG, Canton R et al. Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist. Updat. 14(2), 107-117 (2011
81. Varghese JM, Roberts JA, Lipman J. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit. Care Clin. 27(1), 19-34 (2011
82. Pea F, Viale P. Bench-To-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock -does the dose matter?. Crit. Care 13(3), 214 (2009
83. Lamoth F, Buclin T, Csajka C, Pascual A, Calandra T, Marchetti O. Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies. Antimicrob. Agents Chemother. 53(2), 785-787 (2009
84. Lamoth F, Buclin T, Pascual A, Calandra T, Marchetti O. Imipenem underdosing as a cause of persistent neutropenic fever?. J. Antimicrob. Chemother. 64(3), 665-667 (2009
85. Schliamser SE, Cars O, Norrby SR. Neurotoxicity of beta-lactam antibiotics: Predisposing factors and pathogenesis. J. Antimicrob. Chemother. 27(4), 405-425 (1991
86. Lamoth F, Buclin T, Pascual A et al. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob. Agents Chemother. 54(10), 4360-4367 (2010
87. Afshari A, Pagani L, Harbarth S. Year in review 2011: Critical care -infection. Crit. Care 16(6), 242 (2012
88. Dulhunty JM, Roberts JA, Davis JS et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: A multicenter double-blind, randomized controlled trial. Clin. Infect. Dis. 56(2), 236-244 (2013
89. Chytra I, Stepan M, Benes J et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: A randomized open-label controlled trial. Crit. Care 16(3), R113 (2012
90. De Waele JJ, Tellado JM, Alder J et al. Randomised clinical trial of moxifloxacin versus ertapenem in complicated intraabdominal infections: Results of the PROMISE study. Int. J. Antimicrob. Agents 41(1), 57-64 (2013
91. Demirkaya M, Celebi S, Sevinir B, Hacimustafaoglu M. Randomized comparison of piperacillin-Tazobactam plus amikacin versus cefoperazone- sulbactam plus amikacin for management of febrile neutropenia in children with lymphoma and solid tumors. Pediatr. Hematol. Oncol. 30(2), 141-148 (2013
92. Kern WV, Marchetti O, Drgona L et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: A double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy -EORTC infectious diseases group trial XV. J. Clin. Oncol. 31(9), 1149-1156 (2013
93. Kuroki H, Ishiwada N, Inoue N et al. Comparison of clinical efficacy between 3-day combined clavulanate/amoxicillin preparation treatment and 10-day amoxicillin treatment in children with pharyngolaryngitis or tonsillitis. J. Infect. Chemother. 19(1), 12-19 (2013
94. Little P, Stuart B, Moore M et al. Amoxicillin for acute lower-respiratory-Tract infection in primary care when pneumonia is not suspected: A 12-country, randomised, placebo-controlled trial. Lancet Infect. Dis. 13(2), 123-129 (2013
95. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-Abdominal infections in hospitalized adults: Results of a randomized, double-blind, Phase II trial. J. Antimicrob. Chemother. 68(5), 1183-1192 (2013
96. Manhart LE, Gillespie CW, Lowens MS et al. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: A randomized controlled trial. Clin. Infect. Dis. 56(7), 934-942 (2013
97. Nakagawa Y, Suzuki K, Ohta K et al. Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for patients with hematological disorders and febrile neutropenia. J. Infect. Chemother. 19(1), 103-111 (2013
98. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized Phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-Acquired pneumonia. Antimicrob. Agents Chemother. 57(4), 1756-1762 (2013
99. Quirke M, Wakai A, Gilligan P, O'Sullivan R. Oral flucloxacillin and phenoxymethylpenicillin versus flucloxacillin alone for the emergency department outpatient treatment of cellulitis: Study protocol for a randomised controlled trial. Trials 14, 164 (2013
100. Rex JH, Eisenstein BI, Alder J et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect. Dis. 13(3), 269-275 (2013
101. Chang AB, Grimwood K, Wilson AC et al. Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): Study protocol for a randomized controlled trial. Trials 14, 53 (2013
102. Wunderink RG, Niederman MS, Kollef MH et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: A randomized, controlled study. Clin. Infect. Dis. 54(5), 621-629 (2012
103. Spellberg B. Solving the antibiotic crisis: A top down strategic re-Think. UCLA. www.brookings.edu/~/media/ events/2012/5/09-antibacterial-drug- development/panel-1-brad-spellberg- presentation.pdf
104. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. (EMA/ CHMP/351889/2013). Committee for Medicinal Products for Human Use, EMA. www.ema.europa.eu/docs/en- GB/ document-library/Scientific- guideline/2013/11/WC500153953.pdf
105. Guidance for industry: Hospital-Acquired bacterial pneumonia and ventilator-Associated bacterial pneumonia: Developing drugs for treatment. Revision 1 (UCM234907). US Department of Health and Human Services. www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM234907.pdf
106. Guidance for industry: Antibacterial therapies for patients with unmet medical need for the treatment of serious bacterial diseases (UCM359184). US Department of Health and Humans Services. www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM359184.pdf
107. Kairalla JA, Coffey CS, Thomann MA, Muller KE. Adaptive trial designs: A review of barriers and opportunities. Trials 13, 145 (2012
108. Guidance for industry: Adaptive design clinical trials for drugs and biologics (UCM201790). US Department of Health and Human Services. www.fda.gov/downloads/Drugs// Guidances/ucm201790.pdf
109. COMBACTE. Combating bacterial resistance in Europe. www.combacte.com
110. Talbot GH, Powers JH, Fleming TR et al. Progress on Developing endpoints for registrational clinical trials of communityacquired bacterial pneumonia and acute bacterial skin and skin structure infections: Update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin. Infect. Dis. 55(8), 1114-1121 (2012